Short answer
Neurocrine Biosciences Inc (NBIX) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026 announced.
Neurocrine Biosciences Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026 announced
- Full earnings details and management commentary in Exhibit 99.1
- Results announcement provides the basis for updating revenue, profitability and outlook expectations
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $959M, up 39% YoY, led by INGREZZA $716M, CRENESSITY $184M and newly acquired VYKAT XR $54M
- INGREZZA 2026 sales guidance raised to $2.825B-$2.875B from $2.7B-$2.8B, signaling stronger demand and commercial momentum
- Soleno acquisition completed for $2.9B, adding VYKAT XR and expanding rare-disease exposure, but reducing cash and securities to $482M
- GAAP EPS $1.39 versus $1.06, while non-GAAP EPS reached $2.85 versus $1.65, aided by acquisition-related exclusions
- 2026 GAAP R&D guidance increased to $1.275B-$1.325B and SG&A to $1.575B-$1.6B, reflecting pipeline investment and VYKAT XR commercialization costs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Neurocrine Biosciences Inc 8-K filings
Get the next NBIX 8-K as it lands
Follow NBIX for push alerts, or ask the research agent what this filing means.